Add GlaxoSmithKline to the list of manufacturers that are actually discussing their RFID pilot projects. The company had announced previously that it was sizing up its portfolio for a good candidate on which to test RFID at the item level. Now, it has announced that it has begun tagging individual bottles of its Trizivir HIV medication, a drug listed by the National Association of Boards of Pharmacy as one of the most likely targets for counterfeiting and diversion.
GSK follows Pfizer (the "Little Blue Pill") and Purdue Pharma (Oxycontin). Here's more on those two projects: a discussion with Peggy Staver, Pfizer's RFID leader, and a full account of the Purdue pilot.
RFID Journal has more on the GSK endeavor.
-- PWT
